Apple Podcasts
SpotifyEpisode Description
The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
I The KETO-CTA Study
- JACC Advances Paper: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686
- Meta-analysis https://doi.org/10.1016/j.ajcnut.2024.01.009
II Subclinical AF – Anticoagulate or Not?
Anticoagulation in Subclinical AF May Offer Little Benefit
Treat AFib 'Diagnosed' by Smartwatch
https://www.medscape.com/viewarticle/treat-afib-diagnosed-smartwatch-2025a1000avp
- JAMA NO paper https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2833437
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234
- McIntyre meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
- Singer et al https://pmc.ncbi.nlm.nih.gov/articles/PMC2777526/
- Stroke paper https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.123.045843
- American Journal of Medicine paper https://pubmed.ncbi.nlm.nih.gov/38331136/
III GLP1a for Treatment of Fatty Liver Disease
- ESSENCE trial https://www.nejm.org/doi/10.1056/NEJMoa2413258
Features
- CABG Still Superior to Stents Despite FAME 3 Endpoint Swap
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Proudly Supported by
Patrons of Health Podcast Library
Supporting Shows
